- Home
- TCPC vs ETNB Comparison
TCPC vs ETNB Comparison
Compare TCPC & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCPC
- ETNB
- Stock Information
- Founded
- TCPC 2012
- ETNB 2018
- Country
- TCPC United States
- ETNB United States
- Employees
- TCPC N/A
- ETNB N/A
- Industry
- TCPC Finance/Investors Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- TCPC Finance
- ETNB Health Care
- Exchange
- TCPC Nasdaq
- ETNB Nasdaq
- Market Cap
- TCPC 766.9M
- ETNB 867.4M
- IPO Year
- TCPC 2012
- ETNB 2019
- Fundamental
- Price
- TCPC $8.55
- ETNB $7.94
- Analyst Decision
- TCPC Hold
- ETNB Buy
- Analyst Count
- TCPC 7
- ETNB 7
- Target Price
- TCPC $8.88
- ETNB $30.33
- AVG Volume (30 Days)
- TCPC 602.8K
- ETNB 1.3M
- Earning Date
- TCPC 11-06-2024
- ETNB 11-07-2024
- Dividend Yield
- TCPC 15.91%
- ETNB N/A
- EPS Growth
- TCPC N/A
- ETNB N/A
- EPS
- TCPC N/A
- ETNB N/A
- Revenue
- TCPC $249,036,775.00
- ETNB N/A
- Revenue This Year
- TCPC $27.36
- ETNB N/A
- Revenue Next Year
- TCPC N/A
- ETNB N/A
- P/E Ratio
- TCPC N/A
- ETNB N/A
- Revenue Growth
- TCPC 21.38
- ETNB N/A
- 52 Week Low
- TCPC $7.71
- ETNB $6.43
- 52 Week High
- TCPC $11.99
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- TCPC 38.11
- ETNB 47.27
- Support Level
- TCPC $9.33
- ETNB $6.43
- Resistance Level
- TCPC $9.72
- ETNB $8.09
- Average True Range (ATR)
- TCPC 0.23
- ETNB 0.60
- MACD
- TCPC -0.14
- ETNB -0.07
- Stochastic Oscillator
- TCPC 12.03
- ETNB 48.24
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).